A s demonstrated in other cancer types, the management and outcomes for patients with gestational trophoblastic disease (GTD) have improved with the creation of referral centers. 1 Such centers have developed in the last years in many European, 2, 3 Asian, 4Y7 and South-American countries. 8Y10 Such a referral center has also been created in Canada within the province of Québec in 2009 (Québec Trophoblastic Disease Registry/ Réseau des Maladies Trophoblastiques du Québec-RMTQ). 11 Clinical databases have become critical tools to facilitate optimal patient care, education, and research. However, in the case of rare diseases such as GTD, single institutional databases are insufficient and only multi-institutional (ideally national or multinational) registries can gather significant numbers of patients for these purposes. The RMTQ fulfills this requirement as a registry for referred patients from Quebec, and at least 1 other clinical GTD database is known to exist in Canada. However, no Canada-wide GTD registry currently exists.
We conducted a survey (Supplemental Digital Content 1, http://links.lww.com/IGC/A397) among members of the Canadian Society of Gynecologic Oncology (GOC) to investigate their interest for a pan-Canadian GTD registry. We also took the opportunity to explore their management of GTD.
METHODS
An electronic survey was conducted using Survey Monkey during 5 weeks at the end of 2013. The target group was the entire GOC Canadian Membership who were recruited through their professional e-mail address. Two e-mail reminders were sent out during that period. The survey consisted of 25 questions regarding demographic characteristics of the participants, general information on their practices related to GTD, including pathology, treatment, follow-up, and specific questions focused on issues surrounding registration (see appended Survey). Answers were determined through selection of one of the provided choices for most questions; however, text boxes were provided for participants to provide ''other'' answer in many questions. Only the information most relevant to the present article is described in detail and discussed here.
RESULTS
The survey participation rate was 39% (67/171). Not all responders responded to every question, leaving varied denominators for results reported later.
Most responders (45/62) indicated that they are gynecologic oncologists. With respect to their current practices, 51 (76%) of 67 responders treat patients with molar pregnancy or GTN. Thirty-seven (80%) of 46 treat 5 cases or less of molar pregnancy per year; 36 (80%) of 45 treat 5 cases or less of gestational trophoblastic neoplasia (GTN) per year (Fig. 1) .
Of 49 responders, 48 reported having most of their GTD cases referred from gynecologists and 1 reported having most cases referred from other gynecologists oncologists.
Of 47 respondents, 34 (72%) do not submit molar pregnancy patients to a formal registry and 31 (66%) similarly do not register GTN patients. Of 63 respondents, 58 (92%) believe a registry can (40/63) or probably can (18/63) help patients with GTD. Of 63 respondents, 58 (92%) would register patients if they had access to a registry (Fig. 2) . Responders indicated that the jurisdiction of such a registry should be national (36/61, 59%), provincial (15/61, 25%), and regional (7/61, 11%).
Of 47 responders, 36 (77%) have pathology reviewed for all cases of GTD, but 11 (23%) do not. For those who routinely review pathology, 18 (58%) of 31 use p57 and 18 (58%) of 31 use ploidy as part of the pathology review process.
Of 49 Responders indicated that their practices regarding duration of follow-up required after a suction Dilation and Curettage for a molar pregnancy is based on the following: time to negative hCG (26/46, 57%), pathologic diagnosis (partial vs complete mole; 14/46, 30%), and other factors (6/46, 13%; including a combination of the previous criteria; 6Y12 months, and patients' desire to pursue pregnancy). Similarly, the duration of follow-up after treatment for GTN was based on various factors including WHO risk category; for low-risk GTN (WHO score e6), 38 of 42 responders follow patients for 6 to 12 months after achieving a negative hCG, 4 of 42 follow longer; for high-risk GTN (WHO score Q7), 38 of 45 follow for 2 or more years, 6 follow for 1 year, and 1 respondent based follow-up on the patient's fertility wishes.
In 
DISCUSSION
This survey of GOC members examined their perspectives on a potential pan-Canadian GTD registry and explored their practices regarding GTD management. The overall response rate was modest (37%), and we believe that it is most likely that those GOC members interested in GTD and/or treating patients with GTD were also interested in and responded to this survey. Interestingly, only 76% of respondents to our survey indicated that they actually treat patients with GTD/GTN, which may also contribute to the modest response rate seen to our survey.
In Canada, patients with GTN are referred to gynecologic oncologists universally from gynecologists, and in our experience, it is uncommon in the Canadian health system for gynecologists to refer GTD/GTN cases to a medical oncologist, most of whom are not GOC members. Therefore, we believe that this study captures a representative picture of GTD/GTN practices and management in Canada.
In addition to documenting that not all GOC members treat patients with GTD, this survey also confirms a low level of exposure to trophoblastic disease among GOC members and that most responders (80%) treat 5 affected patients or less per year (Fig. 1) . In fact, a significant proportion (5/46) acknowledges never having encountered a patient with brain metastases. In such complex cases, patients treated by physicians experienced in the management of trophoblastic disease have better survival. 12 These data highlights potential benefit to patient management through creating a pan-Canadian registry linked with experts in GTD management based at referral centers.
Twenty-three percent of responders do not use pathologic review for all GTD cases. In the literature, complete mole is very generally accurately diagnosed by community pathologists. 13 On the contrary, expert pathologic review of partial molar pregnancy changes the diagnosis in 36% of cases, with consequent change in management such as extended follow-up because of a higher risk of associated trophoblastic cancer (change from partial mole to complete mole in 28% of cases), or on the contrary avoidance of unnecessary follow-up and anxiety (change to nonmolar pregnancy with hydropic villi in 7% of cases). 13 Almost half of responders to our survey do not use p57 and/or ploidy studies during pathologic evaluation of GTD cases, both of which are recognized to be helpful in making the right pathologic diagnosis.
14,15 Based on our survey, registration of all GTD cases and management through associated referral centers in Canada would also improve patient care through facilitating routine expert pathologic review.
Responders to our survey were generally knowledgeable about contemporary management issues including duration of follow-up after GTD, the utility of FIGO scoring/ WHO staging and the appropriate treatment of patients with low-and high-risk GTN. However, there are significant variations in the management of GTD among Canadian GOC members, which may simply reflect the paucity of highquality data.
1 Evidence-based practices are more difficult to develop in rare tumors such as GTD. This makes registries particularly important, allowing the collection and analysis of experienced-based data.
Based on the previous considerations, in addition to the benefits to research and education, we believe a pan-Canadian GTD registry is an important next step toward improved outcomes for affected women in Canada. Although currently most responders do not register patients with GTD, almost all responders agreed that a registry may help patients with GTD and indicate that they would register such patients if a registry were available. Most responders consider such a registry should be national in scope, likely reflecting the rarity of these cases to facilitate more uniform management and data collection across the country.
CONCLUSIONS
Gestational trophoblastic diseases are rare entities best managed in a defined system of care, which in many jurisdictions, include mandatory registration of cases and management at expert referral centres. To date, in Canada, GTD management has been largely decentralized and based on local expertise. Within this survey, GOC members acknowledge generally low exposure to GTD patients in Canada and support the creation of a national GTD registry.
In our view, from the Canadian perspective, a realistic proposition for structuring GTD care would be the creation of a national registry including a comprehensive database for epidemiology, education, and research, in addition to several referral centers to facilitate routine pathology review and to help with management of complex cases. The first step FIGURE 2. Survey responses from GOC members regarding commitment to use a GTD registry if one existed. Of 63 responders, 58 (92%) would register their patients.
